ReviewTranslational gastroenterology and hepatology2019
Fecal microbiota transplantation: great potential with many challenges.
Review in Translational gastroenterology and hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).The Cochrane database of systematic reviews · 2023Pooled it
- Mucosal disease activity may predict response to fecal microbiota transplantation in patients with ulcerative colitis.Pediatric research · 2025Article
- The hidden piece in inflammatory bowel diseases: The significance of intestinal mucus in mediating the bacteria-cells crosstalk.Materials today. Bio · 2025Review
- Intestinal Microbiota and Fecal Transplantation in Patients with Inflammatory Bowel Disease andJournal of clinical medicine · 2025Review
- The treatment naïve microbiome of pediatric ulcerative colitis and microbial therapeutics: A humbling challenge.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Article
- Fecal microbiota transplantation and next-generation therapies: A review on targeting dysbiosis in metabolic disorders and beyond.SAGE open medicine · 2024Review
- Parkinson's disease and gut microbiota: from clinical to mechanistic and therapeutic studies.Translational neurodegeneration · 2023Review
- Gut bacterial consortium enriched in a biofloc system protects shrimp against Vibrio parahaemolyticus infection.Microbiome · 2023Article
- The Evolving Landscape of Fecal Microbial Transplantation.Clinical reviews in allergy & immunology · 2023Review
- Fecal microbiota transplantation in childhood: past, present, and future.World journal of pediatrics : WJP · 2023Review
- Efficacy and Safety of Fecal Microbiota Transplantation in Treatment ofMicroorganisms · 2022Review
- Transfer efficiency and impact on disease phenotype of differing methods of gut microbiota transfer.Scientific reports · 2022Article
- Interactions between central nervous system and peripheral metabolic organs.Science China. Life sciences · 2022Review
- Impacts of Gut Microbiota on the Immune System and Fecal Microbiota Transplantation as a Re-Emerging Therapy for Autoimmune Diseases.Antibiotics (Basel, Switzerland) · 2022Review
- MiniBioReactor Array (MBRA)JAC-antimicrobial resistance · 2022Article
- The interplay between anticancer challenges and the microbial communities from the gut.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Review
- Patients and physicians' attitudes change on fecal microbiota transplantation for inflammatory bowel disease over the past 3 years.Annals of translational medicine · 2021Article
- Maternal cecal microbiota transfer rescues early-life antibiotic-induced enhancement of type 1 diabetes in mice.Cell host & microbe · 2021Article
- Knowledge, attitudes, ethical and social perspectives towards fecal microbiota transplantation (FMT) among Jordanian healthcare providers.BMC medical ethics · 2021Observational
- An Immunologic Compatibility Testing Was Not Useful for Donor Selection in Fecal Microbiota Transplantation for Ulcerative Colitis.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In January of 2019, Samuel P. Costello and colleagues published a wonderfully executed, double blind placebo-controlled trial on fecal microbiota transplantation (FMT) versus autologous stool as placebo in mild to moderately active adult ulcerative colitis [UC: one type of inflammatory bowel disease (IBD)] patients. This review-commentary examines the current state of knowledge on human gut microbiome (live microbiota + their products and surrounding environment, i.e., fecal matter) and microbial therapeutics from a gastrointestinal (GI) clinician's standpoint. The varied forms of dysbiosis as the target of FMT, recipient donor and placebo considerations are also discussed in respect to randomized control trials in IBD [and the lack thereof in Crohn's disease (CD)] with this unconventional treatment modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.